Reported 2 days ago
Eli Lilly's diabetes and weight-loss medications, Mounjaro and Zepbound, have been taken off the FDA's shortage list, making them more accessible to consumers. This news may have implications for competing companies such as Novo Nordisk.
Source: YAHOO